Search

Your search keyword '"Abello-Polo V"' showing total 8 results
Start Over Author "Abello-Polo V"
8 results on '"Abello-Polo V"'

1. The Latin American experience of allografting patients with severe aplastic anaemia: real-world data on the impact of stem cell source and ATG administration in HLA-identical sibling transplants

Author

Gómez-Almaguer, D, Vázquez-Mellado, A, Navarro-Cabrera, J R, Abello-Polo, V, Milovic, V, García, J, Basquiera, A L, Saba, S, Balladares, G, Vela-Ojeda, J, Gómez, S, Karduss-Aurueta, A, Bustinza-Álvarez, A, Requejo, A, Feldman, L, Jaime-Pérez, J C, Yantorno, S, Kusminsky, G, Gutiérrez-Aguirre, C H, Arbelbide, J, Martinez-Rolon, J, Jarchum, G, Jaimovich, G, Riera, L, Pedraza-Mesa, E, Villamizar-Gómez, L, Herrera-Rojas, M Á, Gamboa-Alonso, M M, Foncuberta, C, Rodríguez-González, G, García Ruiz-Esparza, M A, Hernández-Maldonado, E, Paz-Infanzón, M, González-López, E, and Ruiz-Argüelles, G J

Published
2017
Full Text
View/download PDF

3. Clinical-Risk Factors that Influence an Optimal Hypomethylating Agents Treatment in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Author

Iastrebner, M., primary, Lazzarino, C., additional, Nucifora, E., additional, Penchasky, D., additional, Fernandez, I., additional, Gusmao Moreno, B.G.M., additional, Rivas, M.M., additional, Espinosa, D., additional, Abello Polo, V., additional, Boada, M., additional, Enrico, A., additional, Araujo Schuster, S., additional, Agra, M., additional, Sarmiento, M., additional, Flores, G., additional, Alfonso, G., additional, Crisp, R., additional, Gusmao Moreno, B., additional, and Consortium, I., additional

Published
2017
Full Text
View/download PDF

4. Lower-Risk Patients that Required Hypomethylating Agents. A Multicentric Experience from Latin America

Author

Iastrebner, M., primary, Belli, C., additional, Lazzarino, C., additional, Fantl, D., additional, Pintos, N., additional, Bengio, R., additional, Prates, M.V., additional, Rosenhain, M., additional, Pose, J., additional, Celebrin, L., additional, Moro, D., additional, Garcia Rivello, H., additional, Grille, S., additional, Flores, G., additional, Rivas, M.M., additional, Enrico, A., additional, Abello Polo, V., additional, Araujo Schuster, S., additional, Arbelbide, J., additional, and Consortium, I., additional

Published
2017
Full Text
View/download PDF

5. The Latin American experience of allografting patients with severe aplastic anaemia: real-world data on the impact of stem cell source and ATG administration in HLA-identical sibling transplants

Author

Gómez-Almaguer, D, primary, Vázquez-Mellado, A, additional, Navarro-Cabrera, J R, additional, Abello-Polo, V, additional, Milovic, V, additional, García, J, additional, Basquiera, A L, additional, Saba, S, additional, Balladares, G, additional, Vela-Ojeda, J, additional, Gómez, S, additional, Karduss-Aurueta, A, additional, Bustinza-Álvarez, A, additional, Requejo, A, additional, Feldman, L, additional, Jaime-Pérez, J C, additional, Yantorno, S, additional, Kusminsky, G, additional, Gutiérrez-Aguirre, C H, additional, Arbelbide, J, additional, Martinez-Rolon, J, additional, Jarchum, G, additional, Jaimovich, G, additional, Riera, L, additional, Pedraza-Mesa, E, additional, Villamizar-Gómez, L, additional, Herrera-Rojas, M Á, additional, Gamboa-Alonso, M M, additional, Foncuberta, C, additional, Rodríguez-González, G, additional, García Ruiz-Esparza, M A, additional, Hernández-Maldonado, E, additional, Paz-Infanzón, M, additional, González-López, E, additional, and Ruiz-Argüelles, G J, additional

Published
2016
Full Text
View/download PDF

8. Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel.

Author

Pavlovsky C, Abello Polo V, Pagnano K, Varela AI, Agudelo C, Bianchini M, Boquimpani C, Centrone R, Conchon M, Delgado N, Funke V, Giere I, Luise I, Meillon L, Moiraghi B, Navarro JR, Pilleux L, Prado AI, Undurraga S, and Cortes J

Subjects
Humans, Polymerase Chain Reaction, Recurrence, Remission Induction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Protein Kinase Inhibitors therapeutic use
Abstract

Tyrosine kinase inhibitors (TKIs) have dramatically changed the survival of chronic myeloid leukemia (CML) patients, and treatment-free remission (TFR) has recently emerged as a new goal of CML treatment. The aim of this work was to develop recommendations for TKI discontinuation in Latin America (LA), outside of clinical trials. A working group of CML experts from LA discussed 22 questions regarding TFR and reached a consensus for TFR recommendations in the region. TFR is indicated in patients in first chronic phase, with typical BCR-ABL transcripts, under TKI treatment of a minimum of 5 years, in sustained deep molecular response (DMR; molecular response 4.5 [MR4.5]) for 2 years. Sustained DMR must be demonstrated on at least 4 international reporting scale quantitative polymerase chain reaction (PCR) tests, separated by at least 3 months, in the immediate prior 2 years. After second-line therapy, TFR is indicated in previously intolerant, not resistant, patients. Molecular monitoring is recommended monthly for the first 6 months, every 2 to 3 months from months 7 to 12, and every 3 months during the second year, indefinitely. Treatment should be reintroduced if major molecular response is lost. Monitoring of withdrawal syndrome, glucose levels, and lipid profile is recommended after discontinuation. After TKI reintroduction, molecular monitoring is indicated every 2 to 3 months until MR4.0 achievement; later, every 3 to 6 months. For the TFR attempt, having standardized and reliable BCR-ABL PCR tests is mandatory. These recommendations will be useful for safe discontinuation in daily practice and will benefit patients who wish to stop treatment in emergent regions, in particular, with TKI-related chronic adverse events., (© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results